乌司他丁治疗病毒性心肌炎临床研究.docVIP

乌司他丁治疗病毒性心肌炎的临床研究 　　【摘要】 目的：探讨乌司他丁治疗病毒性心肌炎患者的有效性。方法：选取2012年5月-2014年5月本院67例患者纳入研究，随机分为试验组33例和对照组34例。试验组在标准治疗基础上给予乌司他丁（30万单位/次，3次/d）治疗，至少5 d；对照组给予等量0.9%氯化钠注射液治疗。根据随访数据绘制生存曲线，入组后28 d评估疗效，并统计有效率和心脏不良事件发生率。结果：试验组和对照组累计死亡率为33.33%（11/33）、35.29%（12/34）。试验组和对照组中位数生存时间分别为15.36、8.82个月，两组生存率比较差异无统计学意义（P=0.135）。试验组有效率63.64%（21/33）高于对照组38.24%（13/34），比较差异有统计学意义（P=0.038）。试验组和对照组心脏不良事件发生率分别为42.42%（14/33）、52.94%（18/34），比较差异无统计学意义（P=0.389）。结论：乌司他丁减轻病毒性心肌炎患者临床症状，但不能降低心脏不良事件发生率和提高生存率 【关键词】 乌司他丁； 病毒性心肌炎； 临床研究； 生存率； 有效率 【Abstract】 Objective：To investigate effectiveness of Ulinastatin in treatment of viral myocarditis.Method：From May 2012 to May 2014，67 patients with viral myocarditis in our hospital were selected，they were randomly divided into experimental group of 33 cases and control group of 34 cases.The treatment group was given Ulinastatin for treatment，at least five days on the basis of standard treatment.The control group was given 0.9% NS for treatment.According to follow-up data，survival curve were drawn，efficacy was evaluated after 28 days，statistics effective rate and incidence of cardiac adverse events were counted.Result：The experimental group and the control group total mortality was 33.33%（11/33），35.29%（12/34）.Experimental group and control group in the median survival time were respectively 15.36 months and 8.82 months，there was no significant difference in the survival rate（P=0.135）.The effective rate of experimental group was 63.64%（21/33） higher than control group 38.24%（13/34），the difference was statistically significant（P=0.038）.The incidence of cardiac adverse events in experimental group and control group were respectively 42.42%（14/33） and 52.94%（18/34），the difference was no statistically significant（P=0.389）.Conclusion：Ulinastatin can alleviate symptom of viral myocarditis，but it can’t decrease incidence of cardiac adverse events or improve survival rate. 【Key words】 Ulinastatin； Viral myocarditis； Clinical study； Survival rate； Effective rate 病毒性心肌炎（v